Proteomics for heart failure risk stratification: a systematic review

Kayode O. Kuku,Rebecca Oyetoro,Maryam Hashemian,Alicia A. Livinski,Joseph J. Shearer,Jungnam Joo,Bruce M. Psaty,Daniel Levy,Peter Ganz and Véronique L. Roger

DOI: https://doi.org/10.1186/s12916-024-03249-7

IF: 9.3

2024-01-26

BMC Medicine

Abstract:Heart failure (HF) is a complex clinical syndrome with persistently high mortality. High-throughput proteomic technologies offer new opportunities to improve HF risk stratification, but their contribution remains to be clearly defined. We aimed to systematically review prognostic studies using high-throughput proteomics to identify protein signatures associated with HF mortality.

medicine, general & internal

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to identify protein markers related to heart failure (HF) mortality by systematically reviewing the application of high - throughput proteomics techniques in heart failure risk stratification. Specifically, the study aims to evaluate the effectiveness of using high - throughput proteomics techniques (such as aptamer platforms and antibody platforms) for death risk stratification in heart failure patients and explore the potential of these techniques in clinical applications.

### Research Background
Heart failure is a complex clinical syndrome. Despite the progress in medical management, its morbidity and mortality remain high. High - throughput proteomics techniques offer new opportunities to improve heart failure risk stratification, but the contribution of these techniques in predicting heart failure death risk has not been clearly defined. Therefore, this article conducts a systematic review to evaluate the application of high - throughput proteomics techniques in heart failure death risk stratification.

### Research Methods
1. **Literature Search**: Researchers searched for relevant articles published from 2012 to 2023 in four databases and two clinical trial registries.
2. **Inclusion Criteria**: The included studies must measure a large number of proteins using aptamer or antibody platforms, and the study subjects are human plasma or serum, and the outcome indicators include all - cause death or cardiovascular death.
3. **Screening and Data Extraction**: Two reviewers independently screened articles, extracted data, and evaluated the risk of bias, and a third reviewer resolved conflicts.
4. **Risk of Bias Assessment**: The ROBINS - E tool was used to assess the risk of bias in non - randomized studies.

### Main Findings
1. **Study Heterogeneity**: A total of 9 studies were included, and these studies had significant heterogeneity in terms of measurement panels, heart failure definitions, ejection fraction classifications, follow - up times, and outcome definitions.
2. **Commonly Identified Proteins**: In two similar aptamer studies, a total of 21 proteins related to all - cause death were identified. Among them, WAP four - disulfide core domain protein 2 was also related to cardiovascular death in an antibody study.
3. **Standardized Reporting Recommendations**: The study proposed standardized reporting criteria to facilitate the interpretation of future studies.

### Conclusions
In this systematic review, researchers identified some proteins that appeared commonly in multiple studies among the nine studies evaluating the relationship between proteomics and heart failure mortality. However, due to the large heterogeneity among the studies, extensive inferences cannot be made, highlighting the importance of standardized reporting methods.

### List of Key Proteins
Table 3 lists 21 proteins related to all - cause death and their functional categories:

| UniProt Number | Protein Name | PANTHER Protein Class |
| ------------- | ------------ | ------------------ |
| P61769 | β2 - microglobulin | Major histocompatibility complex |
| Q86VB7 | Cysteine - rich scavenger receptor class A protein M130 type 1 | Serine protease |
| P09326 | CD48 antigen | Immunoglobulin receptor superfamily |
| P39060 | Collagen alpha1 (XVIII) chain | Extracellular matrix structural protein |
| Q2UY09 | Collagen alpha1 (XXVIII) chain | Extracellular matrix structural protein |
| P12111 | Collagen alpha3 (VI) chain | Extracellular matrix structural protein |
| P01034 | Cystatin C | Protease inhibitor |
| P29317 | Receptor class A member 2 | Protease inhibitor |
| O95633 | Inhibin - related protein 3 | Protease inhibitor |
| Q9UJJ9 | N - acetylglucosamine - 1 - phosphate transferase gamma subunit | Protein - binding activity regulator |
| P28799 | Progranulin | Unassigned class |
| Q14508 | WAP four - disulfide core domain protein 2 | Protease inhibitor |
| P01861 | Immunoglobulin heavy chain constant region gamma4 |